Publications

1. Debeaudrap P, Kabore FN, Setha L, Tegbe J, Doukoure B, Sotheara M, et al. (2025). Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study. Int J Cancer. 156(3): 598-607. https://doi.org/10.1002/ijc.35190 PMID: 39319557
2. Muwonge R, Basu P, consortium IA-IHvs (2025). Re: Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection: Reply to the commentary written by Christine Velicer, Alain Luxembourg, Ya-Ting Chen, Melvin Kohn, and Alfred Saah, Merck & Co., Inc., Kenilworth, NJ, USA on the IARC-India HPV vaccine study. Vaccine. 44: 125062. https://doi.org/10.1016/j.vaccine.2023.06.030 PMID: 37328351
3. Agudelo MC, Agudelo S, Lorincz A, Ramirez AT, Castaneda KM, Garces-Palacio I, et al. (2024). Folate deficiency modifies the risk of CIN3+ associated with DNA methylation levels: a nested case-control study from the ASCUS-COL trial. Eur J Nutr. 63(2): 563-572. https://doi.org/10.1007/s00394-023-03289-4 PMID: 38129362
4. Al-Soneidar WA, Harper S, Coutlee F, Gheit T, Tommasino M, Nicolau B (2024). Prevalence of Alpha, Beta, and Gamma Human Papillomaviruses in patients with head and neck cancer and noncancer controls and relation to behavioral factors. J Infect Dis. 229(4): 1088-1096. https://doi.org/10.1093/infdis/jiad335 PMID: 37584283
5. Arbyn M, Cuschieri K, Bonde J, Schuurman R, Cocuzza C, Broeck DV, et al. (2024). Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening. J Med Virol. 96(9): e29881. https://doi.org/10.1002/jmv.29881 PMID: 39221498
6. Arbyn M, Rousta P, Bruni L, Schollin Ask L, Basu P (2024). Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer. J Natl Cancer Inst. 116(6): 775-778. https://doi.org/10.1093/jnci/djae042 PMID: 38501990
7. Arevalos A, Valenzuela A, Mongelos P, Barrios H, Rodriguez MI, Baez R, et al. (2024). Genital infections in high-risk human papillomavirus positive Paraguayan women aged 30-64 with and without cervical lesions. PLoS One. 19(10): e0312947. https://doi.org/10.1371/journal.pone.0312947 PMID: 39471231
8. Arrossi S, Straw C, Sanchez Antelo V, Paolino M, Baena A, Forestier M, et al. (2024). Implementation of WHO guidelines for cervical cancer screening, diagnosis and treatment: knowledge and perceptions of health providers from Argentina. BMC Cancer. 24(1): 996. https://doi.org/10.1186/s12885-024-12650-7 PMID: 39134975
9. Arroyo Muhr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, et al. (2024). Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun. 15(1): 3679. https://doi.org/10.1038/s41467-024-47909-x PMID: 38693149
10. Asangbeh-Kerman SL, Davidovic M, Taghavi K, Dhokotera T, Manasyan A, Sharma A, et al. (2024). Cervical cancer prevention and care in HIV clinics across sub-Saharan Africa: results of a facility-based survey. J Int AIDS Soc. 27(7): e26303. https://doi.org/10.1002/jia2.26303 PMID: 38979918
11. Basu P, Mwanahamuntu M, Pinder LF, Muwonge R, Lucas E, Nyambe N, et al. (2024). A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial. Nat Med. 30(9): 2596-2604. https://doi.org/10.1038/s41591-024-03080-w PMID: 38918630
12. Becerra-Tomas N, Markozannes G, Cariolou M, Balducci K, Vieira R, Kiss S, et al. (2024). Post-diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis. Int J Cancer. 155(3): 400-425. https://doi.org/10.1002/ijc.34905 PMID: 38692659
13. Beyer K, Leenen R, Venderbos LDF, Helleman J, Denijs F, Bramer W, et al. (2024). Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium. J Pers Med. 14(1): 12. https://doi.org/10.3390/jpm14010084 PMID: 38248785
14. Beyer K, Leenen RCA, Venderbos LDF, Helleman J, Remmers S, Vasilyeva V, et al. (2024). Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey. J Pers Med. 14(7): 12. https://doi.org/10.3390/jpm14070751 PMID: 39064006
15. Boje RB, Bardou M, Mensah K, Rico Berrocal R, Giorgi Rossi P, Bonvicini L, et al. (2024). What are the barriers towards cervical cancer screening for vulnerable women? A qualitative comparative analysis of stakeholder perspectives in seven European countries. BMJ Open. 14(5): e079921. https://doi.org/10.1136/bmjopen-2023-079921 PMID: 38760040
16. Boni SP, Tenet V, Horo A, Heideman DAM, Bleeker MCG, Tanon A, et al. (2024). High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d’Ivoire, 2018 to 2020. Int J Cancer. 154(6): 962-968. https://doi.org/10.1002/ijc.34774 PMID: 37942579
17. Cabanes A, Taylor C, Basu P, Kardinah K, Magsanoc-Alikpala K, Pastrana A (2024). The Role of Civil Society in the Implementation of the Global Breast Cancer Initiative (GBCI) Framework: Takeaways from Southeast Asia. Asian Pac J Cancer Prev. 25(7): 2561-2565. https://doi.org/10.31557/APJCP.2024.25.7.2561 PMID: 39068591
18. Chandran A, van Harten M, Singh D, Vilaseca J, Patasius A, Tupikowski K, et al. (2024). Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U Project. European Urology Open Science. 70: 8-17. https://doi.org/10.1016/j.euros.2024.09.003
19. Clifford GM (2024). Expanding the list of cancers recognized to be caused by infectious agents. J Natl Cancer Inst. 116(12): 1875-1877. https://doi.org/10.1093/jnci/djae185 PMID: 39172647
20. Combes JD, Didelot JM, Radenne S, Zaegel-Faucher O, Lesage AC, Siproudhis L, et al. (2024). Cumulative Detection of Anal High-Grade Squamous Intraepithelial Lesions Over 2-Year Follow-up in Men Who Have Sex With Men Living With Human Immunodeficiency Virus in France. J Infect Dis. 230(1): 55-60. https://doi.org/10.1093/infdis/jiad506 PMID: 39052708
21. Downham L, Jaafar I, Rol ML, Nyawira Nyaga V, Valls J, Baena A, et al. (2024). Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. Br J Cancer. 130(4): 517-525. https://doi.org/10.1038/s41416-023-02490-w PMID: 37973957
22. Downham L, Rol ML, Forestier M, Romero P, Mendoza L, Mongelos P, et al. (2024). Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs. Int J Cancer. 155(5): 816-827. https://doi.org/10.1002/ijc.34953 PMID: 38602045
23. Dube Mandishora RS, Galati L, Reich RR, Combes JD, McKay-Chopin S, Makunike-Mutasa R, et al. (2024). Epstein-Barr Virus DNA Is Associated With Conjunctival Squamous Cell Carcinomas: A Case-Control Study From Zimbabwe. Open Forum Infect Dis. 11(4): ofae165. https://doi.org/10.1093/ofid/ofae165 PMID: 38623569
24. Dusingize JC, Murenzi G, Muhoza B, Businge L, Remera E, Uwinkindi F, et al. (2024). Cancer risk among people living with Human Immunodeficiency Virus (HIV) in Rwanda from 2007 to 2018. Int J Cancer. 155(12): 2149-2158. https://doi.org/10.1002/ijc.35091 PMID: 39128948
25. Engels EA, Shiels MS, Barnabas RV, Bohlius J, Brennan P, Castilho J, et al. (2024). State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI. Int J Cancer. 154(4): 596-606. https://doi.org/10.1002/ijc.34727 PMID: 37715370
26. Fokom Domgue J, Dille I, Gnangnon F, Kapambwe S, Bouchard C, Mbatani N, et al. (2024). Utility of colposcopy for the screening and management of cervical cancer in Africa: a cross-sectional analysis of providers’ training and practices. BMC Health Serv Res. 24(1): 1619. https://doi.org/10.1186/s12913-024-11982-1 PMID: 39695604
27. Fokom Domgue J, Dille I, Kapambwe S, Yu R, Gnangnon F, Chinula L, et al. (2024). HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers’ knowledge, training, and recommendation practices. Front Public Health. 12: 1343064. https://doi.org/10.3389/fpubh.2024.1343064 PMID: 38299075
28. Fuady A, Setiawan D, Man I, de Kok I, Baussano I (2024). Toward a Framework to Assess the Financial and Economic Burden of Cervical Cancer in Low- and Middle-Income Countries: A Systematic Review. JCO Glob Oncol. 10: e2400066. https://doi.org/10.1200/GO.24.00066 PMID: 39116362
29. Garg A, Damgacioglu H, Sigel K, Nyitray AG, Clifford GM, Curran T, et al. (2024). Future patterns in burden and incidence of squamous cell carcinoma of the anus in the United States, 2001-2035. J Natl Cancer Inst. 116(9): 1508-1512. https://doi.org/10.1093/jnci/djae127 PMID: 38837335
30. Guigon L, Sanchez LXG, Petit AS, Bonniec AL, Basu P, Rodrigue CM, et al. (2024). Would shared decision-making be useful in breast cancer screening programmes? A qualitative study using focus group discussions to gather evidence from French women with different socioeconomic backgrounds. BMC Public Health. 24(1): 404. https://doi.org/10.1186/s12889-024-17876-5 PMID: 38326802
31. Gupta P, Venuti A, Savoldy M, Harold A, Zito FA, Taverniti V, et al. (2024). Merkel Cell Polyomavirus targets SET/PP2A complex to promote cellular proliferation and migration. Virology. 597: 110143. https://doi.org/10.1016/j.virol.2024.110143 PMID: 38917692
32. Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Nakawala Chilowa K, et al. (2024). Managing menopause after cancer. Lancet. 403(10430): 984-996. https://doi.org/10.1016/S0140-6736(23)02802-7 PMID: 38458217
33. Kamuyu G, Coelho da Silva F, Tenet V, Schussler J, Godi A, Herrero R, et al. (2024). Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection. Nat Commun. 15(1): 1608. https://doi.org/10.1038/s41467-024-45807-w PMID: 38383518
34. Kartsonaki C, Yao P, Butt J, Jeske R, de Martel C, Plummer M, et al. (2024). Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study. Int J Cancer. 154(8): 1423-1432. https://doi.org/10.1002/ijc.34814 PMID: 38108203
35. Kayamba V, Munshi H, Hankolwe MN, Kaluba Kavimba C, Chongwe G, Knaze V, et al. (2024). Nationwide survey of Helicobacter pylori seropositivity and gastric atrophy in Zambia. Helicobacter. 29(3): e13096. https://doi.org/10.1111/hel.13096 PMID: 38790093
36. Law CCY, Zhang L, Carvalho AL, Rabeneck L, Barkun AN, Nied-Kutterer A, et al. (2024). Canadian colorectal cancer screening programs: How do they measure up using the International Agency for Research on Cancer criteria for organized screening? J Can Assoc Gastroenterol. 7(4): 312-318. https://doi.org/10.1093/jcag/gwae015 PMID: 39139223
37. Lehtinen M, Bruni L, Elfstrom M, Gray P, Logel M, Mariz FC, et al. (2024). Scientific approaches toward improving cervical cancer elimination strategies. Int J Cancer. 154(9): 1537-1548. https://doi.org/10.1002/ijc.34839 PMID: 38196123
38. Lu Y, Clifford GM, Fairley CK, Grulich AE, Garland SM, Xiao F, et al. (2024). Human papillomavirus and p16(INK4a) in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J Cancer. 154(5): 830-841. https://doi.org/10.1002/ijc.34763 PMID: 37861207
39. Mallafre-Larrosa M, Chandran A, Oswal K, Kataria I, Purushotham A, Sankaranarayanan R, et al. (2024). Improving access to cancer care among rural populations in India: Development of a validated tool for health system capacity assessment. Cancer Med. 13(14): e7343. https://doi.org/10.1002/cam4.7343 PMID: 39039809
40. Malvi SG, Esmy PO, Muwonge R, Joshi S, Poli URR, Lucas E, et al. (2024). A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. J Natl Cancer Inst Monogr. 2024(67): 317-328. https://doi.org/10.1093/jncimonographs/lgae042 PMID: 39529521
41. Man I, Georges D, Basu P, Baussano I (2024). Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings. J Natl Cancer Inst Monogr. 2024(67): 400-409. https://doi.org/10.1093/jncimonographs/lgae035 PMID: 39529528
42. Maroui MA, Odongo GA, Mundo L, Manara F, Mure F, Fusil F, et al. (2024). Aflatoxin B1 and Epstein-Barr virus-induced CCL22 expression stimulates B cell infection. Proc Natl Acad Sci U S A. 121(16): e2314426121. https://doi.org/10.1073/pnas.2314426121 PMID: 38574017
43. Martinez-Ramirez J, Saldivia-Siracusa C, Gonzalez-Perez LV, Cuadra Zelaya FJM, Gerber-Mora R, Cabrera OFG, et al. (2024). Barriers to early diagnosis and management of oral cancer in Latin America and the Caribbean. Oral Dis. 30(7): 4174-4184. https://doi.org/10.1111/odi.14903 PMID: 38380784
44. Mensah K, Mosquera I, Tisler A, Uuskula A, Firmino-Machado J, Lunet N, et al. (2024). Development and pilot implementation of a novel protocol to assess capacity and readiness of health systems to adopt HPV detection-based cervical cancer screening in Europe. Health Res Policy Syst. 22(1): 102. https://doi.org/10.1186/s12961-024-01190-y PMID: 39135116
45. Mensah K, Mosquera I, Tisler A, Uuskula A, Firmino-Machado J, Lunet N, et al. (2024). Correction: Development and pilot implementation of a novel protocol to assess capacity and readiness of health systems to adopt HPV detection-based cervical cancer screening in Europe. Health Res Policy Syst. 22(1): 130. https://doi.org/10.1186/s12961-024-01215-6 PMID: 39304883
46. Mosquera I, Barajas CB, Theriault H, Benitez Majano S, Zhang L, Maza M, et al. (2024). Assessment of barriers to cancer screening and interventions implemented to overcome these barriers in 27 Latin American and Caribbean countries. Int J Cancer. 155(4): 719-730. https://doi.org/10.1002/ijc.34950 PMID: 38648380
47. Mrabti H, Sauvaget C, Bendahhou K, Selmouni F, Muwonge R, Lucas E, et al. (2024). Breast cancer treatment and its impact on survival in Morocco: a study over a decade. BMC Cancer. 24(1): 786. https://doi.org/10.1186/s12885-024-12570-6 PMID: 38956536
48. Oommen AM, Ashfaq M, Cherian AG, Colling AM, Ramirez AT, Saunders T, et al. (2024). Strategies and implementation outcomes of HPV-based cervical screening studies to prevent cervical cancer in India: A systematic review. J Cancer Policy. 42: 100513. https://doi.org/10.1016/j.jcpo.2024.100513 PMID: 39510380
49. Pennisi R, Trischitta P, Costa M, Venuti A, Tamburello MP, Sciortino MT (2024). Update of Natural Products and Their Derivatives Targeting Epstein-Barr Infection. Viruses. 16(1): 20. https://doi.org/10.3390/v16010124 PMID: 38257824
50. Ramirez AT, Mesher D, Baena A, Salgado Y, Kasamatsu E, Cristaldo C, et al. (2024). Impact of knowledge of HPV positivity on cervical cytology performance in latin america. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djae283 PMID: 39531343
51. Rugge M, Genta RM, Malfertheiner P, Dinis-Ribeiro M, El-Serag H, Graham DY, et al. (2024). RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut. 73(3): 407-441. https://doi.org/10.1136/gutjnl-2023-331164 PMID: 38383142
52. Saini H, Basu P, Nesari T, Huddar VG, Ray K, Srivastava A, et al. (2024). Therapeutic and pharmacological efficacy of plant-derived bioactive compounds in targeting breast cancer. Am J Transl Res. 16(5): 1499-1520. https://doi.org/10.62347/NUZN4999 PMID: 38883353
53. Sebitloane HM, Forestier M, Ginindza TG, Dhlomo W, Moodley-Govender E, Darragh TM, et al. (2024). Cervical Cancer Screening and Treatment Algorithms Using Human Papillomavirus Testing-Lessons Learnt from a South African Pilot Randomized Controlled Trial. Cancer Epidemiol Biomarkers Prev. 33(6): 779-787. https://doi.org/10.1158/1055-9965.EPI-23-0752 PMID: 37955560
54. Selmouni F, Bendahhou K, Sauvaget C, Abahssain H, Lucas E, Muwonge R, et al. (2024). Impact of clinical breast examination-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco. Cancer. 130(19): 3353-3363. https://doi.org/10.1002/cncr.35419 PMID: 38837217
55. Sichero L, Goncalves MG, Bettoni F, Coser EM, Mota G, Nunes RAL, et al. (2024). Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil. Oral Oncol. 149: 106676. https://doi.org/10.1016/j.oraloncology.2023.106676 PMID: 38150987
56. Singini MG, Muchengeti M, Sitas F, Chen WC, Combes JD, Waterboer T, et al. (2024). Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status. Int J Cancer. 155(2): 251-260. https://doi.org/10.1002/ijc.34919 PMID: 38577820
57. Sjomina O, Polaka I, Suhorukova J, Vangravs R, Parsutins S, Knaze V, et al. (2024). Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation. Eur J Cancer Prev. 33(3): 217-222. https://doi.org/10.1097/CEJ.0000000000000858 PMID: 37942999
58. Sjomina O, Vangravs R, Leonova E, Polaka I, Pupola D, Civkulis K, et al. (2024). Clarithromycin-containing triple therapy for Helicobacter pylori eradication is inducing increased long-term resistant bacteria communities in the gut. Gut. 73(7): 1214-1215. https://doi.org/10.1136/gutjnl-2023-329792 PMID: 37364984
59. Spindler L, Etienney I, Abramowitz L, de Parades V, Pigot F, Siproudhis L, et al. (2024). Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice. Tech Coloproctol. 28(1): 23. https://doi.org/10.1007/s10151-023-02899-8 PMID: 38198036
60. Steinberg J, Hughes S, Hui H, Allsop MJ, Egger S, David M, et al. (2024). Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis. Int J Cancer. 154(8): 1394-1412. https://doi.org/10.1002/ijc.34798 PMID: 38083979
61. Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. (2024). International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 154(10): 1694-1702. https://doi.org/10.1002/ijc.34850 PMID: 38297406
62. Sun D, Mulder DT, Li Y, Nieboer D, Park JY, Suh M, et al. (2024). The Effect of Nationwide Organized Cancer Screening Programs on Gastric Cancer Mortality: A Synthetic Control Study. Gastroenterology. 166(3): 503-514. https://doi.org/10.1053/j.gastro.2023.11.286 PMID: 38007053
63. Van Poppel H, Roobol MJ, Venderbos LD, Basu P, Chandran A, van den Bergh R, et al. (2024). Implications of EU Council Recommendations on Prostate Cancer Screening. BJMO. 3.
64. Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, Majek O, et al. (2024). Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. 86(5): 400-408. https://doi.org/10.1016/j.eururo.2024.04.036 PMID: 38789306
65. Wei F, Georges D, Man I, Baussano I, Clifford GM (2024). Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 404(10451): 435-444. https://doi.org/10.1016/S0140-6736(24)01097-3 PMID: 39097395
66. Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, et al. (2024). Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials. Vaccine X. 19: 100486. https://doi.org/10.1016/j.jvacx.2024.100486 PMID: 38873638
67. Wu T, Lucas E, Zhao F, Basu P, Qiao Y (2024). Artificial intelligence strengthenes cervical cancer screening – present and future. Cancer Biol Med. 21(10): 864-879. https://doi.org/10.20892/j.issn.2095-3941.2024.0198 PMID: 39297572
68. Almadi MA, Basu P (2023). Doing things right and doing the right things: Colorectal cancer screening in Saudi Arabia. Saudi J Gastroenterol. 29(2): 67-70. https://doi.org/10.4103/sjg.sjg_82_23 PMID: 36960528
69. Arbyn M, Costa S, Latsuzbaia A, Kellen E, Girogi Rossi P, Cocuzza CE, et al. (2023). HPV-based Cervical Cancer Screening on Self-samples in the Netherlands: Challenges to Reach Women and Test Performance Questions. Cancer Epidemiol Biomarkers Prev. 32(2): 159-163. https://doi.org/10.1158/1055-9965.EPI-22-1041 PMID: 36744312
70. Baena A, Mesher D, Salgado Y, Martinez S, Villalba GR, Amarilla ML, et al. (2023). Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen-positive women: results from the ESTAMPA study. Int J Cancer. 152(8): 1581-1592. https://doi.org/10.1002/ijc.34384 PMID: 36451311
71. Baena A, Paolino M, Villarreal-Garza C, Torres G, Delgado L, Ruiz R, et al. (2023). Latin America and the Caribbean Code Against Cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening. Cancer Epidemiol. 86 Suppl 1: 102446. https://doi.org/10.1016/j.canep.2023.102446 PMID: 37852728
72. Bhatla N, Muwonge R, Malvi SG, Joshi S, Poli URR, Lucas E, et al. (2023). Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine. Hum Vaccin Immunother. 19(3): 2289242. https://doi.org/10.1080/21645515.2023.2289242 PMID: 38078840
73. Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, et al. (2023). XPERT((R)) breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 17: 1530. https://doi.org/10.3332/ecancer.2023.1530 PMID: 37138965
74. Brevik TB, da Matta Calegari LR, Metcalfe IM, Laake P, Maza M, Basu P, et al. (2023). Training health care providers to administer VIA as a screening test for cervical cancer: a systematic review of essential training components. BMC Med Educ. 23(1): 712. https://doi.org/10.1186/s12909-023-04711-5 PMID: 37770904
75. Burger E, Baussano I, Kim JJ, Laprise JF, Berkhof J, Schiller JT, et al. (2023). Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions. Vaccine. 41(16): 2648-2649. https://doi.org/10.1016/j.vaccine.2022.07.022 PMID: 35941035
76. Ceraolo MG, Romero-Medina MC, Gobbato S, Melita G, Krynska H, Sirand C, et al. (2023). HPV38 impairs UV-induced transcriptional activation of the IL-18 pro-inflammatory cytokine. mSphere. 8(6): e0045023. https://doi.org/10.1128/msphere.00450-23 PMID: 37877723
77. Clifford GM, Baussano I, Heideman DAM, Tshering S, Choden T, Lazzarato F, et al. (2023). Human papillomavirus testing on self-collected samples to detect high-grade cervical lesions in rural Bhutan: The REACH-Bhutan study. Cancer Med. 12(10): 11828-11837. https://doi.org/10.1002/cam4.5851 PMID: 36999740
78. Clifford GM, Wei F (2023). Prevention of Human Papillomavirus-Related Anal Cancer in Women Living With Human Immunodeficiency Virus. J Infect Dis. 227(8): 929-931. https://doi.org/10.1093/infdis/jiac399 PMID: 36196561
79. Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. (2023). Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 8(4): 332-342. https://doi.org/10.1016/S2468-1253(22)00386-7 PMID: 36764320
80. Damgacioglu H, Lin YY, Ortiz AP, Wu CF, Shahmoradi Z, Shyu SS, et al. (2023). State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States. J Clin Oncol. 41(6): 1228-1238. https://doi.org/10.1200/JCO.22.01390 PMID: 36441987
81. de Carvalho TM, Man I, Georges D, Saraswati LR, Bhandari P, Kataria I, et al. (2023). Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India. BMJ Glob Health. 8(11): e012580. https://doi.org/10.1136/bmjgh-2023-012580 PMID: 37931940
82. Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Clifford GM (2023). Human Papillomavirus-Associated Anal Cancer Incidence and Burden Among US Men, According to Sexual Orientation, Human Immunodeficiency Virus Status, and Age. Clin Infect Dis. 77(3): 419-424. https://doi.org/10.1093/cid/ciad205 PMID: 37017078
83. Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Ferlay J, Bray F, et al. (2023). Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis. Int J Cancer. 152(3): 417-428. https://doi.org/10.1002/ijc.34269 PMID: 36054026
84. Espina C, Feliu A, Maza M, Almonte M, Ferreccio C, Finck C, et al. (2023). Latin America and the Caribbean Code Against Cancer 1st Edition: 17 cancer prevention recommendations to the public and to policy-makers (World Code Against Cancer Framework). Cancer Epidemiol. 86 Suppl 1: 102402. https://doi.org/10.1016/j.canep.2023.102402 PMID: 37852725
85. Galati L, Gupta P, Tufaro A, Marinaro M, Saponaro C, Escobar Marcillo DI, et al. (2023). Evaluation of human papillomavirus DNA in colorectal cancer and adjacent mucosal tissue samples. Infect Agent Cancer. 18(1): 71. https://doi.org/10.1186/s13027-023-00552-5 PMID: 37941001
86. Gheit T, Muwonge R, Lucas E, Galati L, Anantharaman D, McKay-Chopin S, et al. (2023). Impact of HPV vaccination on HPV-related oral infections. Oral Oncol. 136: 106244. https://doi.org/10.1016/j.oraloncology.2022.106244 PMID: 36402055
87. Gomez Rivas J, Leenen RCA, Venderbos LDF, Helleman J, de la Parra I, Vasilyeva V, et al. (2023). Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs. J Pers Med. 13(12): 13. https://doi.org/10.3390/jpm13121677 PMID: 38138904
88. Gu J, He F, Clifford GM, Li M, Fan Z, Li X, et al. (2023). A systematic review and meta-analysis on the relative and attributable risk of Helicobacter pylori infection and cardia and non-cardia gastric cancer. Expert Rev Mol Diagn. 23(12): 1251-1261. https://doi.org/10.1080/14737159.2023.2277377 PMID: 37905778
89. Hall MT, Simms KT, Murray JM, Keane A, Nguyen DTN, Caruana M, et al. (2023). Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV. Nat Med. 29(12): 3059-3066. https://doi.org/10.1038/s41591-023-02601-3 PMID: 38087116
90. Hirabayashi M, Georges D, Clifford GM, de Martel C (2023). Estimating the Global Burden of Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 21(4): 922-930 e921. https://doi.org/10.1016/j.cgh.2022.07.042 PMID: 35963539
91. Hirabayashi M, Traverse-Glehen A, Combes JD, Clifford GM, de Martel C (2023). Estimating the prevalence of Epstein-Barr virus in primary gastric lymphoma: a systematic review and meta-analysis. Infect Agent Cancer. 18(1): 8. https://doi.org/10.1186/s13027-023-00482-2 PMID: 36765388
92. Hu SY, Zhao XL, Zhao FH, Wei LH, Zhou Q, Niyazi M, et al. (2023). Implementation of visual inspection with acetic acid and Lugol’s iodine for cervical cancer screening in rural China. Int J Gynaecol Obstet. 160(2): 571-578. https://doi.org/10.1002/ijgo.14368 PMID: 35871356
93. Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, et al. (2023). Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature. Fam Cancer. 22(3): 283-289. https://doi.org/10.1007/s10689-023-00331-6 PMID: 37119509
94. Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C, Basu P (2023). Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials. BMJ Open. 13(10): e069616. https://doi.org/10.1136/bmjopen-2022-069616 PMID: 37879679
95. Ikiroma A, Santin O, Camanda J, Chocolate F, Pelinganga O, Jordao H, et al. (2023). Evaluation of human papillomavirus (HPV) knowledge among healthcare professionals: A study of conference attendees in Angola. Glob Public Health. 18(1): 2099931. https://doi.org/10.1080/17441692.2022.2099931 PMID: 35849621
96. Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al. (2023). Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 41(1): 236-245. https://doi.org/10.1016/j.vaccine.2022.11.044 PMID: 36446654
97. Joshi S, Muwonge R, Kulkarni V, Mandolkar M, Lucas E, Pujari S, et al. (2023). Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, India. Int J Cancer. 152(2): 249-258. https://doi.org/10.1002/ijc.34221 PMID: 35852007
98. Knaze V, Freisling H, Cook P, Heise K, Acevedo J, Cikutovic M, et al. (2023). Association between salt intake and gastric atrophy by Helicobacter pylori infection: first results from the Epidemiological Investigation of Gastric Malignancy (ENIGMA). Eur J Nutr. 62(5): 2129-2138. https://doi.org/10.1007/s00394-023-03132-w PMID: 36964250
99. Kutz JM, Rausche P, Gheit T, Puradiredja DI, Fusco D (2023). Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review. BMC Public Health. 23(1): 974. https://doi.org/10.1186/s12889-023-15842-1 PMID: 37237329
100. Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Friedlaender A, et al. (2023). Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Med Wkly. 153: 40055. https://doi.org/10.57187/smw.2023.40055 PMID: 37011610
101. Li M, Park JY, Sheikh M, Kayamba V, Rumgay H, Jenab M, et al. (2023). Population-based investigation of common and deviating patterns of gastric cancer and oesophageal cancer incidence across populations and time. Gut. 72(5): 846-854. https://doi.org/10.1136/gutjnl-2022-328233 PMID: 36241389
102. Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D, et al. (2023). Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 72(12): 2354-2363. https://doi.org/10.1136/gutjnl-2023-330691 PMID: 37798085
103. Lucas E, Murillo R, Arrossi S, Barcena M, Chami Y, Nessa A, et al. (2023). Quantification of impact of COVID-19 pandemic on cancer screening programmes – a case study from Argentina, Bangladesh, Colombia, Morocco, Sri Lanka, and Thailand. Elife. 12: e86527. https://doi.org/10.7554/eLife.86527 PMID: 37191660
104. Mallafre-Larrosa M, Ritchie D, Papi G, Mosquera I, Mensah K, Lucas E, et al. (2023). Survey of current policies towards widening cervical screening coverage among vulnerable women in 22 European countries. Eur J Public Health. 33(3): 502-508. https://doi.org/10.1093/eurpub/ckad055 PMID: 37043751
105. Man I, Georges D, Bonjour M, Baussano I (2023). Approximating missing epidemiological data for cervical cancer through Footprinting: A case study in India. Elife. 12: e81752. https://doi.org/10.7554/eLife.81752 PMID: 37227260
106. Man I, Georges D, Sankaranarayanan R, Basu P, Baussano I (2023). Building resilient cervical cancer prevention through gender-neutral HPV vaccination. Elife. 12. https://doi.org/10.7554/eLife.85735 PMID: 37486822
107. Mosquera I, Barajas CB, Zhang L, Lucas E, Benitez Majano S, Maza M, et al. (2023). Assessment of organization of cervical and breast cancer screening programmes in the Latin American and the Caribbean states: The CanScreen5 framework. Cancer Med. 12(19): 19935-19948. https://doi.org/10.1002/cam4.6492 PMID: 37768035
108. Mosquera I, Todd A, Balaj M, Zhang L, Benitez Majano S, Mensah K, et al. (2023). Components and effectiveness of patient navigation programmes to increase participation to breast, cervical and colorectal cancer screening: A systematic review. Cancer Med. 12(13): 14584-14611. https://doi.org/10.1002/cam4.6050 PMID: 37245225
109. Mullapally SK, Basu P, Parikh P (2023). Prevention of Cervical Cancer through HPV Vaccination and Screening in Maldives. South Asian J Cancer. 12(1): 44-46. https://doi.org/10.1055/s-0043-1764158 PMID: 36851935
110. Ong SK, Abe SK, Thilagaratnam S, Haruyama R, Pathak R, Jayasekara H, et al. (2023). Towards elimination of cervical cancer – human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries. Lancet Reg Health West Pac. 39: 100860. https://doi.org/10.1016/j.lanwpc.2023.100860 PMID: 37576906
111. Oommen AM, Basu P, Cherian AG, Zomawia E, Manoharan R, Pricilla RA, et al. (2023). Protocol for the formative phase of a trial (SHE-CAN) to test co-designed implementation strategies for HPV-based cervical screening among vulnerable women in two diverse settings in India. Implement Sci Commun. 4(1): 62. https://doi.org/10.1186/s43058-023-00436-0 PMID: 37291627
112. Pham TM, Thanh NX, Ng N, Kubo T, Fujino Y, Matsuda S, et al. (2023). Average lifespan shortened due to cancer in selected countries of North America, Europe, Asia and Oceania, 2006 and 2016. Ann Epidemiol. 80: 76-85. https://doi.org/10.1016/j.annepidem.2023.01.012 PMID: 36717062
113. Ramadas K, Basu P, Mathew BS, Muwonge R, Venugopal M, Prakasan AM, et al. (2023). Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India. Cancer. 129(2): 272-282. https://doi.org/10.1002/cncr.34526 PMID: 36321193
114. Ramirez AT, Valls J, Baena A, Rojas FD, Ramírez K, Álvarez R, et al. (2023). Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study. The Lancet Regional Health – Americas. 26: 100593. https://doi.org/10.1016/j.lana.2023.100593 PMID: 37766799
115. Salimzadeh H, Sauvaget C, Delavari A, Sadeghi A, Amani M, Salimzadeh S, et al. (2023). Colorectal Cancer Screening Pilot Project in Tehran-Iran, a Feasibility Study. Arch Iran Med. 26(3): 138-146. https://doi.org/10.34172/aim.2023.22 PMID: 37543936
116. Sauvaget C, Boutayeb S, Bendahhou K, Selmouni F, Belbaraka R, Muwonge R, et al. (2023). The journey of cancer patients and the quest to equity: findings from Morocco. Public Health. 223: 33-41. https://doi.org/10.1016/j.puhe.2023.07.015 PMID: 37597462
117. Sauvaget C, Selmouni F, Dangbemey DP, Kpebo DDO, Dieng NM, Nkele NN, et al. (2023). Scaling-Up Cervical Cancer Screening and Treatment in Sub-Saharan Africa: Perspectives From Local Health Policymakers. JCO Glob Oncol. 9: e2300115. https://doi.org/10.1200/GO.23.00115 PMID: 37441744
118. Sayinzoga F, Tenet V, Heideman DAM, Sibomana H, Umulisa MC, Franceschi S, et al. (2023). Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys. Lancet Glob Health. 11(7): e1096-e1104. https://doi.org/10.1016/S2214-109X(23)00193-6 PMID: 37207683
119. Schuind AE, Rees H, Schiller J, Mugo N, Dull P, Barnabas R, et al. (2023). State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop. Prev Med Rep. 35: 102331. https://doi.org/10.1016/j.pmedr.2023.102331 PMID: 37576844
120. Shaji A, Keechilat P, Dk V, Sauvaget C (2023). Analysis of the Mortality Trends of 23 Major Cancers in the Indian Population Between 2000 and 2019: A Joinpoint Regression Analysis. JCO Glob Oncol. 9: e2200405. https://doi.org/10.1200/GO.22.00405 PMID: 36947728
121. Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, et al. (2023). Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Lancet Oncol. 24(12): 1321-1333. https://doi.org/10.1016/S1470-2045(23)00480-1 PMID: 37949086
122. Simms KT, Keane A, Nguyen DTN, Caruana M, Hall MT, Lui G, et al. (2023). Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nat Med. 29(12): 3050-3058. https://doi.org/10.1038/s41591-023-02600-4 PMID: 38087115
123. Taghavi K, Zhao F, Downham L, Baena A, Basu P (2023). Molecular triaging options for women testing HPV positive with self-collected samples. Front Oncol. 13: 1243888. https://doi.org/10.3389/fonc.2023.1243888 PMID: 37810963
124. Valls J, Baena A, Venegas G, Celis M, Gonzalez M, Sosa C, et al. (2023). Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study. Lancet Glob Health. 11(3): e350-e360. https://doi.org/10.1016/S2214-109X(22)00545-9 PMID: 36796982
125. Van Poppel H, Roobol MJ, Chandran AD (2023). Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U. Eur Urol. 84(6): 519-522. https://doi.org/10.1016/j.eururo.2023.08.002 PMID: 37704541
126. Vazquez-Juárez D, González-Sánchez DG, Andrade-Moreno RA, Villarreal-Garza C (2023). Perception of healthcare system delays and referral pathways for breast cancer care in Mexico: a PhysiciansÓ? survey. Gaceta Mexicana de Oncologa. 22(3): 114-121. https://doi.org/10.24875/j.gamo.230001071
127. Waheed DEN, Burdier FR, Eklund C, Baussano I, Mariz FC, Teblick L, et al. (2023). An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses – A meeting report. Preventive Medicine Reports. 35: 102368. https://doi.org/10.1016/j.pmedr.2023.102368 PMID: 37680853
128. Wei F, Alberts CJ, Albuquerque A, Clifford GM (2023). Impact of Human Papillomavirus Vaccine Against Anal Human Papillomavirus Infection, Anal Intraepithelial Neoplasia, and Recurrence of Anal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis. J Infect Dis. 228(11): 1496-1504. https://doi.org/10.1093/infdis/jiad183 PMID: 37257044
129. Wei F, Goodman MT, Xia N, Zhang J, Giuliano AR, D’Souza G, et al. (2023). Incidence and Clearance of Anal Human Papillomavirus Infection in 16 164 Individuals, According to Human Immunodeficiency Virus Status, Sex, and Male Sexuality: An International Pooled Analysis of 34 Longitudinal Studies. Clin Infect Dis. 76(3): e692-e701. https://doi.org/10.1093/cid/ciac581 PMID: 35869839
130. Wei F, Xia N, Ocampo R, Goodman MT, Hessol NA, Grinsztejn B, et al. (2023). Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. J Infect Dis. 227(4): 488-497. https://doi.org/10.1093/infdis/jiac108 PMID: 35325151
131. Wijstma ES, Jongen VW, Alberts CJ, de Melker HE, Hoes J, Schim van der Loeff MF (2023). Approaches to Estimating Clearance Rates for Human Papillomavirus Groupings: A Systematic Review and Real Data Examples. Epidemiology. 34(1): 119-130. https://doi.org/10.1097/EDE.0000000000001550 PMID: 36137191
132. Xia C, Basu P, Kramer BS, Li H, Qu C, Yu XQ, et al. (2023). Cancer screening in China: a steep road from evidence to implementation. Lancet Public Health. 8(12): e996-e1005. https://doi.org/10.1016/S2468-2667(23)00186-X PMID: 38000379
133. Yao P, Kartsonaki C, Butt J, Jeske R, de Martel C, Plummer M, et al. (2023). Helicobacter pylori multiplex serology and risk of non-cardia and cardia gastric cancer: a case-cohort study and meta-analysis. Int J Epidemiol. 52(4): 1197-1208. https://doi.org/10.1093/ije/dyad007 PMID: 36913255
134. Zhang L, Mosquera I, Lucas E, Rol ML, Carvalho AL, Basu P, et al. (2023). CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. Nat Med. 29(5): 1135-1145. https://doi.org/10.1038/s41591-023-02315-6 PMID: 37106168
135. Zhang L, Sauvaget C, Mosquera I, Basu P (2023). Efficacy, acceptability and safety of ablative versus excisional procedure in the treatment of histologically confirmed CIN2/3: A systematic review. BJOG. 130(2): 153-161. https://doi.org/10.1111/1471-0528.17251 PMID: 35689493
136. Zhao XL, Zhao S, Xia CF, Hu SY, Duan XZ, Liu ZH, et al. (2023). Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study. BMC Med. 21(1): 149. https://doi.org/10.1186/s12916-023-02840-8 PMID: 37069602
137. Znaor A, Ryzhov A, Losada ML, Carvalho A, Smelov V, Barchuk A, et al. (2023). Breast and cervical cancer screening practices in nine countries of Eastern Europe and Central Asia: A population-based survey. J Cancer Policy. 38: 100436. https://doi.org/10.1016/j.jcpo.2023.100436 PMID: 37544479
138. Adebamowo SN, Befano B, Cheung LC, Rodriguez AC, Demarco M, Rydzak G, et al. (2022). Different human papillomavirus types share early natural history transitions in immunocompetent women. Int J Cancer. 151(6): 920-929. https://doi.org/10.1002/ijc.34128 PMID: 35603904
139. Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, et al. (2022). Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 7(8): 724-735. https://doi.org/10.1016/S2468-1253(22)00050-4 PMID: 35576953
140. Alhomoud S, Al-Othman S, Al-Madouj A, Homsi MA, AlSaleh K, Balaraj K, et al. (2022). Progress and remaining challenges for cancer control in the Gulf Cooperation Council. Lancet Oncol. 23(11): e493-e501. https://doi.org/10.1016/S1470-2045(22)00488-0 PMID: 36328023
141. Amorrortu RP, Zhao Y, Fenske NA, Cherpelis BS, Messina JL, Giuliano AR, et al. (2022). Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections. J Infect Dis. 226(7): 1162-1174. https://doi.org/10.1093/infdis/jiac004 PMID: 35022780
142. Asangbeh-Kerman SL, Davidovic M, Taghavi K, Kachingwe J, Rammipi KM, Muzingwani L, et al. (2022). Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies. BMC Public Health. 22(1): 1530. https://doi.org/10.1186/s12889-022-13827-0 PMID: 35948944
143. Baisley K, Kemp TJ, Kreimer AR, Basu P, Changalucha J, Hildesheim A, et al. (2022). Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. Lancet Glob Health. 10(10): e1485-e1493. https://doi.org/10.1016/S2214-109X(22)00306-0 PMID: 36113532
144. Banerjee D, Mittal S, Mandal R, Basu P (2022). Screening technologies for cervical cancer: Overview. Cytojournal. 19: 23. https://doi.org/10.25259/CMAS_03_04_2021 PMID: 35510117
145. Banila C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, Kumbi B, Beyene D, et al. (2022). Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. Int J Cancer. 150(2): 290-302. https://doi.org/10.1002/ijc.33815 PMID: 34562270
146. Basiletti JA, Valls J, Poklepovich T, Fellner MD, Rol M, Alonso R, et al. (2022). Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections. PLoS One. 17(11): e0278117. https://doi.org/10.1371/journal.pone.0278117 PMID: 36417453
147. Basu P, Carvalho AL, Almonte M, Chajes V, Weiderpass E (2022). Pulling the investment levers on implementation research in oncology. Lancet Oncol. 23(4): 451-452. https://doi.org/10.1016/S1470-2045(22)00025-0 PMID: 35358451
148. Basu P, Muwonge R (2022). Alternative analysis of the data from a HPV vaccine study in India – Authors’ reply. Lancet Oncol. 23(1): e10. https://doi.org/10.1016/S1470-2045(21)00729-4 PMID: 34973220
149. Benider A, Bendahhou K, Sauvaget C, Mrabti H, Selmouni F, Muwonge R, et al. (2022). Evolution of patterns of care for women with cervical cancer in Morocco over a decade. BMC Cancer. 22(1): 479. https://doi.org/10.1186/s12885-022-09358-x PMID: 35501742
150. Broutet N, Jeronimo J, Kumar S, Almonte M, Murillo R, Huy NVQ, et al. (2022). Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. Prev Med. 155: 106906. https://doi.org/10.1016/j.ypmed.2021.106906 PMID: 34896155
151. Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. (2022). Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 10(8): e1115-e1127. https://doi.org/10.1016/S2214-109X(22)00241-8 PMID: 35839811
152. Chargari C, Arbyn M, Leary A, Abu-Rustum NR, Basu P, Bray F, et al. (2022). Increasing global accessibility to high-level treatments for cervical cancers. Gynecol Oncol. 164(1): 231-241. https://doi.org/10.1016/j.ygyno.2021.10.073 PMID: 34716024
153. Chiantore MV, Iuliano M, Mongiovi RM, Dutta S, Tommasino M, Di Bonito P, et al. (2022). The E6 and E7 proteins of beta3 human papillomavirus 49 can deregulate both cellular and extracellular vesicles-carried microRNAs. Infect Agent Cancer. 17(1): 29. https://doi.org/10.1186/s13027-022-00445-z PMID: 35705991
154. Clasen JL, Heath AK, Van Puyvelde H, Huybrechts I, Park JY, Ferrari P, et al. (2022). Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Int J Cancer. 151(5): 708-716. https://doi.org/10.1002/ijc.34009 PMID: 35366005
155. Correa RM, Baena A, Valls J, Colucci MC, Mendoza L, Rol M, et al. (2022). Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America. PLoS One. 17(7): e0272205. https://doi.org/10.1371/journal.pone.0272205 PMID: 35905130
156. Damgacioglu H, Sonawane K, Chhatwal J, Lairson DR, Clifford GM, Giuliano AR, et al. (2022). Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. Lancet Reg Health Am. 8: 100143. https://doi.org/10.1016/j.lana.2021.100143 PMID: 34927126
157. Dhokotera T, Asangbeh S, Bohlius J, Singh E, Egger M, Rohner E, et al. (2022). Cervical cancer in women living in South Africa: a record linkage study of the National Health Laboratory Service and the National Cancer Registry. Ecancermedicalscience. 16: 1348. https://doi.org/10.3332/ecancer.2022.1348 PMID: 35242229
158. Dias JM, Santana IVV, da Silva VD, Carvalho AL, Arantes L (2022). Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region. Int J Mol Sci. 23(19). https://doi.org/10.3390/ijms231911720 PMID: 36233023
159. Donzel M, Bonjour M, Combes JD, Broussais F, Sesques P, Traverse-Glehen A, et al. (2022). Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. EClinicalMedicine. 54: 101674. https://doi.org/10.1016/j.eclinm.2022.101674 PMID: 36204003
160. Duan R, Zhang H, Wu A, Li C, Li L, Xu X, et al. (2022). Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. Sex Transm Infect. 98(4): 247-254. https://doi.org/10.1136/sextrans-2021-055019 PMID: 34187906
161. Fokom Domgue J, Pande M, Yu R, Manjuh F, Welty E, Welty T, et al. (2022). Development, Implementation, and Evaluation of a Distance Learning and Telementoring Program for Cervical Cancer Prevention in Cameroon. JAMA Netw Open. 5(11): e2240801. https://doi.org/10.1001/jamanetworkopen.2022.40801 PMID: 36346631
162. Galati L, Combes JD, Le Calvez-Kelm F, McKay-Chopin S, Forey N, Ratel M, et al. (2022). Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay. Microbiol Spectr. 10(2): e0148021. https://doi.org/10.1128/spectrum.01480-21 PMID: 35225653
163. Gallus R, Gheit T, Holzinger D, Petrillo M, Rizzo D, Petrone G, et al. (2022). Prevalence of HPV Infection and p16(INK4a) Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma. Vaccines (Basel). 10(2): 13. https://doi.org/10.3390/vaccines10020204 PMID: 35214663
164. Geng CX, Tanamal P, Arvisais-Anhalt S, Tomasino M, Gheit T, Bishop JA, et al. (2022). Clinical and Biologic Characteristics and Outcomes in Young and Middle-Aged Patients With Laryngeal Cancer: A Retrospective Cohort Analysis. Otolaryngol Head Neck Surg. 167(4): 688-698. https://doi.org/10.1177/01945998211073707 PMID: 35077266
165. Ginindza TG, Forestier M, Almonte M (2022). Cervical cancer screening by visual inspection and HPV testing in Eswatini. Prev Med. 161: 107144. https://doi.org/10.1016/j.ypmed.2022.107144 PMID: 35810934
166. Hariprasad R, Mittal S, Basu P (2022). Role of colposcopy in the management of women with abnormal cytology. Cytojournal. 19: 40. https://doi.org/10.25259/CMAS_03_15_2021 PMID: 35928528
167. Hu SY, Kreimer AR, Porras C, Guillen D, Alfaro M, Darragh TM, et al. (2022). Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial. J Natl Cancer Inst. 114(9): 1253-1261. https://doi.org/10.1093/jnci/djac107 PMID: 35640980
168. Ibrahim Khalil A, Franceschi S, de Martel C, Bray F, Clifford GM (2022). Burden of Kaposi sarcoma according to HIV status: A systematic review and global analysis. Int J Cancer. 150(12): 1948-1957. https://doi.org/10.1002/ijc.33951 PMID: 35085400
169. Ibrahim Khalil A, Mpunga T, Wei F, Baussano I, de Martel C, Bray F, et al. (2022). Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. Int J Cancer. 150(5): 761-772. https://doi.org/10.1002/ijc.33841 PMID: 34626498
170. Lebeau A, Bruyere D, Roncarati P, Peixoto P, Hervouet E, Cobraiville G, et al. (2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nat Commun. 13(1): 1076. https://doi.org/10.1038/s41467-022-28724-8 PMID: 35228537
171. Leja M, Cine E, Polaka I, Daugule I, Murillo R, Parshutin S, et al. (2022). Factors influencing participation in preventive interventions for gastric cancer: the results from the GISTAR study. Eur J Cancer Prev. 31(2): 128-136. https://doi.org/10.1097/CEJ.0000000000000682 PMID: 34519690
172. Li M, Zhang L, Charvat H, Callister ME, Sasieni P, Christodoulou E, et al. (2022). The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials. Int J Cancer. 151(9): 1491-1501. https://doi.org/10.1002/ijc.34167 PMID: 35809038
173. Lopez-Filloy M, Cortez FJ, Gheit T, Cruz YCO, Cruz-Talonia F, Chavez-Torres M, et al. (2022). Altered Vaginal Microbiota Composition Correlates With Human Papillomavirus and Mucosal Immune Responses in Women With Symptomatic Cervical Ectopy. Front Cell Infect Microbiol. 12: 884272. https://doi.org/10.3389/fcimb.2022.884272 PMID: 35656032
174. Lourencao M, Simoes Correa Galendi J, Galvao HCR, Antoniazzi AP, Grasel RS, Carvalho AL, et al. (2022). Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country. Front Oncol. 12: 951310. https://doi.org/10.3389/fonc.2022.951310 PMID: 35898894
175. Makau-Barasa LK, Manirakiza A, Carvalho AL, Rebbeck TR (2022). Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis. Cancer Control. 29: 10732748221084932. https://doi.org/10.1177/10732748221084932 PMID: 35350915
176. Man I, Georges D, de Carvalho TM, Ray Saraswati L, Bhandari P, Kataria I, et al. (2022). Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study. Lancet Oncol. 23(11): 1419-1429. https://doi.org/10.1016/S1470-2045(22)00543-5 PMID: 36174583
177. Mao JJ, Pillai GG, Andrade CJ, Ligibel JA, Basu P, Cohen L, et al. (2022). Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA Cancer J Clin. 72(2): 144-164. https://doi.org/10.3322/caac.21706 PMID: 34751943
178. Matos LL, Capuzzo RC, Pedruzzi PAG, Farias T, de Farias JWM, Chone CT, et al. (2022). Sentinel lymph node biopsy for early squamous cell carcinoma of the lip and oral cavity: Real-world experience in Brazil. Head Neck. 44(7): 1604-1615. https://doi.org/10.1002/hed.27061 PMID: 35427429
179. Mosquera I, Ilbawi A, Muwonge R, Basu P, Carvalho AL (2022). Cancer burden and status of cancer control measures in fragile states: a comparative analysis of 31 countries. Lancet Glob Health. 10(10): e1443-e1452. https://doi.org/10.1016/S2214-109X(22)00331-X PMID: 36113529
180. Mpunga T, Clifford GM, Morgan EA, Milner DA, Jr., de Martel C, Munyanshongore C, et al. (2022). Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. Int J Cancer. 150(5): 753-760. https://doi.org/10.1002/ijc.33840 PMID: 34626122
181. Mwanahamuntu M, Kapambwe S, Pinder LF, Matambo J, Chirwa S, Chisele S, et al. (2022). The use of thermal ablation in diverse cervical cancer “screen-and-treat” service platforms in Zambia. Int J Gynaecol Obstet. 157(1): 85-89. https://doi.org/10.1002/ijgo.13808 PMID: 34197624
182. Parak U, Lopes Carvalho A, Roitberg F, Mandrik O (2022). Effectiveness of screening for oral cancer and oral potentially malignant disorders (OPMD): A systematic review. Prev Med Rep. 30: 101987. https://doi.org/10.1016/j.pmedr.2022.101987 PMID: 36189128
183. Prudden HJ, Achilles SL, Schocken C, Broutet N, Canfell K, Akaba H, et al. (2022). Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022. Vaccine. 40(41): 5843-5855. https://doi.org/10.1016/j.vaccine.2022.08.020 PMID: 36008233
184. Razuka-Ebela D, Polaka I, Daugule I, Parshutin S, Santare D, Ebela I, et al. (2022). Lifestyle and dietary factors associated with serologically detected gastric atrophy in a Caucasian population in the GISTAR study. Eur J Cancer Prev. 31(5): 442-450. https://doi.org/10.1097/CEJ.0000000000000723 PMID: 35131967
185. Razuka-Ebela D, Polaka I, Daugule I, Parshutin S, Santare D, Ebela I, et al. (2022). Factors Associated with False Negative Results in Serum Pepsinogen Testing for Precancerous Gastric Lesions in a European Population in the GISTAR Study. Diagnostics (Basel). 12(5): 11. https://doi.org/10.3390/diagnostics12051166 PMID: 35626319
186. Ritchie D, Arbyn M, Basu P, Corbex M, Fidarova E, Ivanus U, et al. (2022). Europe’s Path to Eliminating Cervical Cancer as a Public Health Problem. Lancet Reg Health Eur. 12: 100276. https://doi.org/10.1016/j.lanepe.2021.100276 PMID: 34901914
187. Rol ML, Picconi MA, Ferrera A, Sanchez GI, Hernandez ML, Lineros J, et al. (2022). Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study. Front Med (Lausanne). 9: 1006038. https://doi.org/10.3389/fmed.2022.1006038 PMID: 36465901
188. Saponaro C, Galati L, Gheit T, Pappagallo SA, Zambetti M, Zito FA, et al. (2022). Alteration of Na/H exchange regulatory factor-1 protein levels in anogenital lesions positive for mucosal high-risk human papillomavirus type 16. Virology. 576: 69-73. https://doi.org/10.1016/j.virol.2022.09.004 PMID: 36179457
189. Sauvaget C, Bazikamwe S, Lucas E, Ndayikengurukiye A, Harerimana S, Barango P (2022). Evaluation of effectiveness, acceptability and safety of thermal ablation in the treatment of cervical neoplasia in Burundi. Int J Cancer. 151(7): 1120-1126. https://doi.org/10.1002/ijc.34117 PMID: 35567576
190. Schulte-Frohlinde R, Georges D, Clifford GM, Baussano I (2022). Predicting Cohort-Specific Cervical Cancer Incidence From Population-Based Surveys of Human Papilloma Virus Prevalence: A Worldwide Study. Am J Epidemiol. 191(3): 402-412. https://doi.org/10.1093/aje/kwab254 PMID: 34652438
191. Selmouni F, Amrani L, Sauvaget C, Bakkar M, El Khannoussi B, Souadka A, et al. (2022). Delivering colorectal cancer screening integrated with primary health care services in Morocco: Lessons learned from a demonstration project. Cancer. 128(6): 1219-1229. https://doi.org/10.1002/cncr.34061 PMID: 34985785
192. Selmouni F, Guy M, Muwonge R, Nassiri A, Lucas E, Basu P, et al. (2022). Effectiveness of Artificial Intelligence-Assisted Decision-making to Improve Vulnerable Women’s Participation in Cervical Cancer Screening in France: Protocol for a Cluster Randomized Controlled Trial (AppDate-You). JMIR Res Protoc. 11(8): e39288. https://doi.org/10.2196/39288 PMID: 35771872
193. Selmouni F, Sauvaget C, Dangbemey DP, Kpebo DDO, Dieng NM, Lucas E, et al. (2022). Lessons Learnt From Pilot Cervical Cancer Screening and Treatment Programmes Integrated to Routine Primary Health Care Services in Benin, Cote d’Ivoire, and Senegal. JCO Glob Oncol. 8: e2200051. https://doi.org/10.1200/GO.22.00051 PMID: 36070534
194. Sharkey Ochoa I, O’Regan E, Toner M, Kay E, Faul P, O’Keane C, et al. (2022). The Role of HPV in Determining Treatment, Survival, and Prognosis of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 14(17): 4321. https://doi.org/10.3390/cancers14174321 PMID: 36077856
195. Shastri SS, Temin S, Almonte M, Basu P, Campos NG, Gravitt PE, et al. (2022). Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update. JCO Glob Oncol. 8: e2200217. https://doi.org/10.1200/GO.22.00217 PMID: 36162041
196. Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, et al. (2022). Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 23(7): 940-949. https://doi.org/10.1016/S1470-2045(22)00291-1 PMID: 35709811
197. Sichero L, Tagliabue M, Mota G, Ferreira S, Nunes RAL, Castaneda CA, et al. (2022). Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16(INK4a) status. Head Neck. 44(1): 122-133. https://doi.org/10.1002/hed.26912 PMID: 34726297
198. Sierra MS, Tsang SH, Porras C, Herrero R, Sampson JN, Cortes B, et al. (2022). Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial. Sex Transm Infect. 99(3): 180-186. https://doi.org/10.1136/sextrans-2022-055434 PMID: 35842229
199. Simoens C, Gheit T, Ridder R, Gorbaslieva I, Holzinger D, Lucas E, et al. (2022). Accuracy of high-risk HPV DNA PCR, p16((INK4a)) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. BMC Infect Dis. 22(1): 676. https://doi.org/10.1186/s12879-022-07654-2 PMID: 35933382
200. Sjomina O, Lielause A, Rudule A, Vangravs R, Parsutins S, Polaka I, et al. (2022). Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication. Eur J Cancer Prev. 31(4): 333-338. https://doi.org/10.1097/CEJ.0000000000000718 PMID: 35471812
201. Skakkebaek NE, Lindahl-Jacobsen R, Levine H, Andersson AM, Jorgensen N, Main KM, et al. (2022). Environmental factors in declining human fertility. Nat Rev Endocrinol. 18(3): 139-157. https://doi.org/10.1038/s41574-021-00598-8 PMID: 34912078
202. Skrebinska S, Megraud F, Daugule I, Santare D, Isajevs S, Liepniece-Karele I, et al. (2022). Who Could Be Blamed in the Case of Discrepant Histology and Serology Results for Helicobacter pylori Detection? Diagnostics (Basel). 12(1). https://doi.org/10.3390/diagnostics12010133 PMID: 35054298
203. Smelov V, Trusova O, Barbier S, Muwonge R, Grankov V, Rusovich V, et al. (2022). Rationale and Purpose: The FLUTE Study to Evaluate Fluorography Mass Screening for Tuberculosis and Other Diseases, as Conducted in Eastern Europe and Central Asia Countries. Int J Environ Res Public Health. 19(14): 8706. https://doi.org/10.3390/ijerph19148706 PMID: 35886558
204. Tsang SH, Schiller JT, Porras C, Kemp TJ, Herrero R, Schussler J, et al. (2022). HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial. NPJ Vaccines. 7(1): 40. https://doi.org/10.1038/s41541-022-00431-x PMID: 35351898
205. Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M (2022). Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 19(9): 562-572. https://doi.org/10.1038/s41585-022-00638-6 PMID: 35974245
206. Veljkovikj I, Ilbawi AM, Roitberg F, Luciani S, Barango P, Corbex M, et al. (2022). Evolution of the joint International Atomic Energy Agency (IAEA), International Agency for Research on Cancer (IARC), and WHO cancer control assessments (imPACT Reviews). Lancet Oncol. 23(10): e459-e468. https://doi.org/10.1016/S1470-2045(22)00387-4 PMID: 36174632
207. Vicente A, Novoloaca A, Cahais V, Awada Z, Cuenin C, Spitz N, et al. (2022). Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure. Nat Commun. 13(1): 4115. https://doi.org/10.1038/s41467-022-31488-w PMID: 35840550
208. Yao P, Millwood I, Kartsonaki C, Mentzer AJ, Allen N, Jeske R, et al. (2022). Sero-prevalence of 19 infectious pathogens and associated factors among middle-aged and elderly Chinese adults: a cross-sectional study. BMJ Open. 12(5): e058353. https://doi.org/10.1136/bmjopen-2021-058353 PMID: 35534062
209. Yuan T, Hu Y, Zhou X, Yang L, Wang H, Li L, et al. (2022). Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 52: 101613. https://doi.org/10.1016/j.eclinm.2022.101613 PMID: 35990580
210. Zhang L, Carvalho AL, Mosquera I, Wen T, Lucas E, Sauvaget C, et al. (2022). An international consensus on the essential and desirable criteria for an ‘organized’ cancer screening programme. BMC Med. 20(1): 101. https://doi.org/10.1186/s12916-022-02291-7 PMID: 35317783
211. Zhang L, Zhao X, Hu S, Chen S, Zhao S, Dong L, et al. (2022). Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: Results from a prospective cohort study. Int J Cancer. 151(6): 878-887. https://doi.org/10.1002/ijc.34041 PMID: 35460075
212. Zhao S, Huang L, Basu P, Domingo EJ, Supakarapongkul W, Ling WY, et al. (2022). Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. Cancer Lett. 525: 22-32. https://doi.org/10.1016/j.canlet.2021.10.036 PMID: 34728309
213. Aglago EK, Murphy N, Huybrechts I, Nicolas G, Casagrande C, Fedirko V, et al. (2021). Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Int J Cancer. 149(4): 865-882. https://doi.org/10.1002/ijc.33615 PMID: 33913149
214. Albuquerque A, Baptista PV, Clifford GM (2021). For Anal Cancer, Not All Women Are Equal. Am J Gastroenterol. 116(10): 2140. https://doi.org/10.14309/ajg.0000000000001298 PMID: 34618701
215. Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, et al. (2021). Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 30(9): 1761-1764. https://doi.org/10.1158/1055-9965.EPI-21-0332 PMID: 34187857
216. Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. (2021). The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 148(2): 277-284. https://doi.org/10.1002/ijc.33189 PMID: 32638362
217. Arbyn M, Simon M, Peeters E, Xu L, Meijer C, Berkhof J, et al. (2021). 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 27(8): 1083-1095. https://doi.org/10.1016/j.cmi.2021.04.031 PMID: 33975008
218. Basu P, Alhomoud S, Taghavi K, Carvalho AL, Lucas E, Baussano I (2021). Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation. JCO Glob Oncol. 7: 416-424. https://doi.org/10.1200/GO.21.00033 PMID: 33784177
219. Basu P, Lucas E, Zhang L, Muwonge R, Murillo R, Nessa A (2021). Leveraging vertical COVID-19 investments to improve monitoring of cancer screening programme – A case study from Bangladesh. Prev Med. 151: 106624. https://doi.org/10.1016/j.ypmed.2021.106624 PMID: 34023359
220. Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. (2021). Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 22(11): 1518-1529. https://doi.org/10.1016/S1470-2045(21)00453-8 PMID: 34634254
221. Basu P, Tripathi R, Mehrotra R, Ray K, Srivastava A, Srivastava A (2021). Role of integrative medicine in the continuum of care of breast cancer patients in the Indian context. Cancer Causes Control. 32(5): 429-440. https://doi.org/10.1007/s10552-021-01399-0 PMID: 33528692
222. Baussano I, Sayinzoga F, Tshomo U, Tenet V, Vorsters A, Heideman DAM, et al. (2021). Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. Emerg Infect Dis. 27(1): 1-9. https://doi.org/10.3201/eid2701.191364 PMID: 33350922
223. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2021). Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 155 Suppl 1: 28-44. https://doi.org/10.1002/ijgo.13865 PMID: 34669203
224. Bhatla N, Nessa A, Oswal K, Vashist S, Sebastian P, Basu P (2021). Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. Int J Gynaecol Obstet. 152(1): 40-47. https://doi.org/10.1002/ijgo.13486 PMID: 33205399
225. Bonjour M, Charvat H, Franco EL, Pineros M, Clifford GM, Bray F, et al. (2021). Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. 6(7): e510-e521. https://doi.org/10.1016/S2468-2667(21)00046-3 PMID: 33864738
226. Brancaccio RN, Robitaille A, Dutta S, Rollison DE, Tommasino M, Gheit T (2021). MinION nanopore sequencing and assembly of a complete human papillomavirus genome. J Virol Methods. 294: 114180. https://doi.org/10.1016/j.jviromet.2021.114180 PMID: 33965458
227. Brotherton JML, Wheeler C, Clifford GM, Elfstrom M, Saville M, Kaldor J, et al. (2021). Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. Prev Med. 144: 106293. https://doi.org/10.1016/j.ypmed.2020.106293 PMID: 33075352
228. Caicedo-Martinez M, Fernandez-Deaza G, Ordonez-Reyes C, Olejua P, Nuche-Berenguer B, Mello MB, et al. (2021). High-risk human papillomavirus infection among women living with HIV in Latin America and the Caribbean: A systematic review and meta-analysis. Int J STD AIDS. 32(14): 1278-1289. https://doi.org/10.1177/09564624211037498 PMID: 34488503
229. Cheung LC, Ramadas K, Muwonge R, Katki HA, Thomas G, Graubard BI, et al. (2021). Risk-Based Selection of Individuals for Oral Cancer Screening. J Clin Oncol. 39(6): 663-674. https://doi.org/10.1200/JCO.20.02855 PMID: 33449824
230. Chung MH, De Vuyst H, Greene SA, Mugo NR, Querec TD, Nyongesa-Malava E, et al. (2021). Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 7(10): 1514-1520. https://doi.org/10.1001/jamaoncol.2021.2683 PMID: 34351377
231. Chung MH, De Vuyst H, Greene SA, Topazian HM, Sayed S, Moloo Z, et al. (2021). Loop electrosurgical excision procedure (LEEP) plus top hat for HIV-infected women with endocervical intraepithelial neoplasia in Kenya. Int J Gynaecol Obstet. 152(1): 118-124. https://doi.org/10.1002/ijgo.13466 PMID: 33145753
232. Clasen JL, Heath AK, Van Puyvelde H, Huybrechts I, Park JY, Ferrari P, et al. (2021). A comparison of complementary measures of vitamin B6 status, function, and metabolism in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 114(1): 338-347. https://doi.org/10.1093/ajcn/nqab045 PMID: 33829249
233. Clifford GM, Alberts CJ (2021). Molecular Risk Stratification for Anal Cancer Prevention. Clin Infect Dis. 72(12): 2164-2166. https://doi.org/10.1093/cid/ciaa399 PMID: 32266927
234. Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. (2021). A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 148(1): 38-47. https://doi.org/10.1002/ijc.33185 PMID: 32621759
235. Combes JD, Voisin N, Perie S, Malard O, Jegoux F, Nadjingar R, et al. (2021). History of tonsillectomy and risk of oropharyngeal cancer. Oral Oncol. 117: 105302. https://doi.org/10.1016/j.oraloncology.2021.105302 PMID: 33905915
236. Dillner J, Elfstrom KM, Baussano I (2021). Prospects for accelerated elimination of cervical cancer. Prev Med. 153: 106827. https://doi.org/10.1016/j.ypmed.2021.106827 PMID: 34599922
237. Drolet M, Laprise JF, Martin D, Jit M, Benard E, Gingras G, et al. (2021). Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infect Dis. 21(11): 1598-1610. https://doi.org/10.1016/S1473-3099(20)30860-4 PMID: 34245682
238. Dube Mandishora RS, Rounge TB, Fitzpatrick M, Christiansen IK, Ambur OH, Lagstrom S, et al. (2021). Self-collected and clinician-collected anal swabs show modest agreement for HPV genotyping. PLoS One. 16(4): e0250426. https://doi.org/10.1371/journal.pone.0250426 PMID: 33901223
239. Duffell E, Cortez-Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, et al. (2021). Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. J Viral Hepat. 28(8): 1177-1189. https://doi.org/10.1111/jvh.13545 PMID: 34003542
240. Escriva-Boulley G, Mandrik O, Preau M, Herrero R, Villain P (2021). Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review. Prev Med. 143: 106323. https://doi.org/10.1016/j.ypmed.2020.106323 PMID: 33171178
241. Fadhil I, Alkhalawi E, Nasr R, Fouad H, Basu P, Camacho R, et al. (2021). National cancer control plans across the Eastern Mediterranean region: challenges and opportunities to scale-up. Lancet Oncol. 22(11): e517-e529. https://doi.org/10.1016/S1470-2045(21)00410-1 PMID: 34735820
242. Ferreiro-Iglesias A, McKay JD, Brenner N, Virani S, Lesseur C, Gaborieau V, et al. (2021). Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer. Nat Commun. 12(1): 5945. https://doi.org/10.1038/s41467-021-26151-9 PMID: 34642315
243. Galati L, Brancaccio RN, Gupta P, Lohmann E, Robitaille A, Mandishora RSD, et al. (2021). Diversity of human papillomavirus in the anal canal of HIV-positive and HIV-negative men. J Infect. 82(1): 112-116. https://doi.org/10.1016/j.jinf.2020.11.030 PMID: 33253726
244. Gama RR, Arantes L, Sorroche BP, De Marchi P, Melendez ME, Carvalho RS, et al. (2021). Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. Sci Rep. 11(1): 16415. https://doi.org/10.1038/s41598-021-95845-3 PMID: 34385507
245. Ginsburg O, Basu P, Kapambwe S, Canfell K (2021). Eliminating cervical cancer in the COVID-19 era. Nat Cancer. 2(2): 133-134. https://doi.org/10.1038/s43018-021-00178-9 PMID: 35122078
246. Giorgi Rossi P, Carozzi F, Ronco G, Allia E, Bisanzi S, Gillio-Tos A, et al. (2021). p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. J Natl Cancer Inst. 113(3): 292-300. https://doi.org/10.1093/jnci/djaa105 PMID: 32745170
247. Giraldi L, Collatuzzo G, Hashim D, Franceschi S, Herrero R, Chen C, et al. (2021). Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer. Cancer Epidemiol. 75: 102020. https://doi.org/10.1016/j.canep.2021.102020 PMID: 34509873
248. Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer C, et al. (2021). Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 148(2): 320-328. https://doi.org/10.1002/ijc.33207 PMID: 32663316
249. Jongen VW, van der Loeff MFS, Boyd A, Petrignani M, Prins M, van der Wal M, et al. (2021). Human papillomavirus vaccination uptake: a longitudinal study showing ethnic differences in the influence of the intention-to-vaccinate among parent-daughter dyads. Hum Vaccin Immunother. 17(4): 990-999. https://doi.org/10.1080/21645515.2020.1808411 PMID: 32966170
250. Joshi S, Muwonge R, Kulkarni V, Lucas E, Kulkarni S, Kand S, et al. (2021). Mobile Screening Unit (MSU) for the Implementation of the ‘Screen and Treat’ Programme for Cervical Cancer Prevention In Pune, India. Asian Pac J Cancer Prev. 22(2): 413-418. https://doi.org/10.31557/APJCP.2021.22.2.413 PMID: 33639655
251. Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ (2021). Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol. 21(1): 95. https://doi.org/10.1186/s12876-021-01680-1 PMID: 33653284
252. Kumar S, Khanduri A, Sidibe A, Morgan C, Torode J, Basu P, et al. (2021). Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 152(1): 32-39. https://doi.org/10.1002/ijgo.13482 PMID: 33185283
253. Lesseur C, Ferreiro-Iglesias A, McKay JD, Bosse Y, Johansson M, Gaborieau V, et al. (2021). Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. PLoS Genet. 17(3): e1009254. https://doi.org/10.1371/journal.pgen.1009254 PMID: 33667223
254. Li M, Delafosse P, Meheus F, Borson-Chazot F, Lifante JC, Simon R, et al. (2021). Temporal and geographical variations of thyroid cancer incidence and mortality in France during 1986-2015: The impact of overdiagnosis. Cancer Epidemiol. 75: 102051. https://doi.org/10.1016/j.canep.2021.102051 PMID: 34743057
255. Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB (2021). Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer. Int J Womens Health. 13: 841-859. https://doi.org/10.2147/IJWH.S288376 PMID: 34566436
256. Magnotti F, Valsesia S, Gupta P, Flechtenmacher C, Contard P, Viarisio D, et al. (2021). The Inflammasome Adaptor ASC Delays UV-Induced Skin Tumorigenesis in Beta HPV38 E6 and E7 Transgenic Mice. J Invest Dermatol. 141(1): 236-238 e232. https://doi.org/10.1016/j.jid.2020.04.028 PMID: 32470340
257. Matos LL, Forster CHQ, Marta GN, Castro Junior G, Ridge JA, Hirata D, et al. (2021). The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model. Cancer Causes Control. 32(5): 459-471. https://doi.org/10.1007/s10552-021-01411-7 PMID: 33704627
258. Mattoscio D, Gheit T, Strati K, Venuti A (2021). Editorial: HPV and Host Interaction. Front Cell Infect Microbiol. 11: 638005. https://doi.org/10.3389/fcimb.2021.638005 PMID: 33777848
259. Miranda-Filho A, Charvat H, Bray F, Migowski A, Cheung LC, Vaccarella S, et al. (2021). A modeling analysis to compare eligibility strategies for lung cancer screening in Brazil. EClinicalMedicine. 42: 101176. https://doi.org/10.1016/j.eclinm.2021.101176 PMID: 34765952
260. Mrabti H, Sauvaget C, Benider A, Bendahhou K, Selmouni F, Muwonge R, et al. (2021). Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade. Breast. 59: 193-202. https://doi.org/10.1016/j.breast.2021.07.009 PMID: 34280610
261. Mrabti H, Sauvaget C, Benider A, Bendahhou K, Selmouni F, Muwonge R, et al. (2021). Reply to: Chronic pain assessment and management during post-treatment follow up should be considered as a high value quality indicator for specialist breast cancer center. Breast. 60: 309. https://doi.org/10.1016/j.breast.2021.09.003 PMID: 34509362
262. Ortmann O, Torode J, Schmiegel W, Thomssen C, Hakama M, Basu P, et al. (2021). Correction to: Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. J Cancer Res Clin Oncol. 147(12): 3773. https://doi.org/10.1007/s00432-021-03709-0 PMID: 34213663
263. Park JY, Herrero R (2021). Recent progress in gastric cancer prevention. Best Pract Res Clin Gastroenterol. 50-51: 101733. https://doi.org/10.1016/j.bpg.2021.101733 PMID: 33975687
264. Pimenoff VN, Elfstrom M, Baussano I, Bjornstedt M, Dillner J (2021). Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. Clin Infect Dis. 72(11): e890-e892. https://doi.org/10.1093/cid/ciaa1593 PMID: 33070183
265. Pineros M, Saraiya M, Baussano I, Bonjour M, Chao A, Bray F (2021). The role and utility of population-based cancer registries in cervical cancer surveillance and control. Prev Med. 144: 106237. https://doi.org/10.1016/j.ypmed.2020.106237 PMID: 33678223
266. Pinheiro M, Harari A, Schiffman M, Clifford GM, Chen Z, Yeager M, et al. (2021). Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses. 13(10): 19. https://doi.org/10.3390/v13101948 PMID: 34696378
267. Polaka I, Razuka-Ebela D, Park JY, Leja M (2021). Taxonomy-based data representation for data mining: an example of the magnitude of risk associated with H. pylori infection. BioData Min. 14(1): 43. https://doi.org/10.1186/s13040-021-00271-w PMID: 34454568
268. Ramirez AT, Sanchez GI, Nedjai B, Agudelo MC, Brentnall AR, Cuschieri K, et al. (2021). Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country. Int J Cancer. 148(6): 1383-1393. https://doi.org/10.1002/ijc.33314 PMID: 33006394
269. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schuz J, et al. (2021). The Porto European Cancer Research Summit 2021. Mol Oncol. 15(10): 2507-2543. https://doi.org/10.1002/1878-0261.13078 PMID: 34515408
270. Rollison DE, Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, et al. (2021). Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Res. 81(17): 4628-4638. https://doi.org/10.1158/0008-5472.CAN-21-0805 PMID: 34266893
271. Sierra MS, Tsang SH, Hu S, Porras C, Herrero R, Kreimer AR, et al. (2021). Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. J Infect Dis. 224(3): 503-516. https://doi.org/10.1093/infdis/jiaa768 PMID: 33326576
272. Simoens C, Gorbaslieva I, Gheit T, Holzinger D, Lucas E, Ridder R, et al. (2021). HPV DNA genotyping, HPV E6*I mRNA detection, and p16(INK4a)/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. Cancer Epidemiol. 72: 101925. https://doi.org/10.1016/j.canep.2021.101925 PMID: 33839457
273. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. (2021). Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 9(2): e161-e169. https://doi.org/10.1016/S2214-109X(20)30459-9 PMID: 33212031
274. Tota JE, Struyf F, Hildesheim A, Gonzalez P, Ryser M, Herrero R, et al. (2021). Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. J Infect Dis. 223(9): 1576-1581. https://doi.org/10.1093/infdis/jiaa561 PMID: 32887990
275. Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al. (2021). Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: Study from the IARC COVID-19 impact study group. Int J Cancer. 149(1): 97-107. https://doi.org/10.1002/ijc.33500 PMID: 33533501
276. Wei F, Gaisa MM, D’Souza G, Xia N, Giuliano AR, Hawes SE, et al. (2021). Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV. 8(9): e531-e543. https://doi.org/10.1016/S2352-3018(21)00108-9 PMID: 34339628
277. Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, et al. (2021). Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 19(1): 62. https://doi.org/10.1186/s12916-021-01930-9 PMID: 33653331
278. Yadav K, Ginsburg O, Basu P, Mehrotra R (2021). Telemedicine and Cancer Care in Low- and Middle-Income Countries During the SARS-CoV-2 Pandemic. JCO Glob Oncol. 7: 1633-1638. https://doi.org/10.1200/GO.21.00249 PMID: 34860567
279. Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. (2021). The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health. 6(12): e888-e896. https://doi.org/10.1016/S2468-2667(21)00164-X PMID: 34838195
280. Zhao XL, Liu ZH, Zhao S, Hu SY, Muwonge R, Duan XZ, et al. (2021). Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. Int J Cancer. 148(6): 1419-1427. https://doi.org/10.1002/ijc.33290 PMID: 32895912
281. Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, et al. (2021). Cutaneous viral infections associated with ultraviolet radiation exposure. Int J Cancer. 148(2): 448-458. https://doi.org/10.1002/ijc.33263 PMID: 32818302